Zimmer Biomet Holdings Inc. ($ZBH) Stock Forecast: Up 5.3% Today

What is Zimmer Biomet Holdings Inc.?

Zimmer Biomet Holdings Inc. (ZBH) specializes in orthopedic reconstructive products, and recently, its stock showed a significant uptrend.

Why is Zimmer Biomet Holdings Inc. going up?

ZBH stock is up 5.3% on Feb 10, 2026 14:56

• Strong fourth-quarter financial results from Zimmer Biomet exceeded revenue and earnings predictions, leading to the stock's upward trend.
• Despite the positive results, the company's cautious approach to its 2026 guidance, citing the ever-changing healthcare landscape, initially caused a slight decline in pre-market stock prices.
• The strategic shift towards a direct and specialized sales model in the U.S., as highlighted by the CEO, likely bolstered investor confidence in the company's future growth.
• A newly announced $1.5 billion stock repurchase program also contributed to positive investor sentiment and the stock's upward trajectory.

ZBH Price Chart

ZBH Technical Analysis

ZBH News

Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance

Zimmer Biomet exceeded its Q4 expectations, reporting $1.94 billion in revenue against an estimated $1.89 billion, and adjusted earnings per share of $2.20, beating the $2.09 consensus. Despite this strong performance, the company adopted a cautious outlook for its 2026 forecast, with its CEO emphasizing a "balanced perspective" on future growth due to the dynamic healthcare environment. The company provided its 2024 guidance, projecting revenues between $7.67 billion and $7.75 billion, and adjusted earnings per share of $8.00 to $8.15.

https://www.msn.com/en-us/money/companies/zimmer-biomet-tops-q4-expectations-but-strikes-measured-tone-on-2026-guidance/ar-AA1W3DWQ?ocid=finance-verthp-feeds

Zimmer: Q4 Earnings Snapshot

Zimmer Biomet Holdings Inc. (ZBH) reported strong fourth-quarter results, surpassing Wall Street expectations. The company announced a net income of $139.3 million, or 70 cents per share, with adjusted earnings of $2.42 per share, beating analyst estimates of $2.38. Revenue for the quarter reached $2.24 billion, also exceeding forecasts, and the full-year profit stood at $705.1 million on $8.23 billion in revenue.

https://www.kens5.com/article/syndication/associatedpress/zimmer-q4-earnings-snapshot/616-1c48ba4d-a0e1-430e-8549-09453c703ea8

Earnings Flash (ZBH) Zimmer Biomet Holdings, Inc. Reports Q4 Revenue $2.24B, vs. FactSet Est of $2.22B

Zimmer Biomet Holdings, Inc. (ZBH) announced its Q4 revenue reached $2.24 billion, surpassing FactSet's estimate of $2.22 billion. The company also reported Q4 adjusted EPS of $2.42 per share, significantly exceeding FactSet's estimate of $1.79. Additionally, Zimmer Biomet provided its full-year 2026 adjusted EPS outlook, ranging from $8.30 to $8.45, against FactSet's estimate of $8.46.

https://www.marketscreener.com/news/earnings-flash-zbh-zimmer-biomet-holdings-inc-reports-q4-revenue-2-24b-vs-factset-est-of-2-2-ce7e5adcd98ff121

Zimmer Biomet posts Q4 beats, sets 2026 guidance

Zimmer Biomet exceeded consensus forecasts for Q4 2025, with adjusted EPS hitting $2.42 and sales reaching $2.24 billion. Despite a slight dip in share price pre-market, the company reported significant strategic progress in 2025 and provided 2026 sales growth guidance of 2.5% to 4.5% and adjusted EPS between $8.30 and $8.45. The guidance reflects a strategic shift to a predominantly direct and specialized sales organization in the U.S., which the CEO believes will drive long-term growth.

https://www.massdevice.com/zimmer-biomet-q4-2025-beats-guidance/

Zimmer Biomet delivers Q4 earnings beat, cautious 2026 outlook By Investing.com

Zimmer Biomet (NYSE:ZBH) reported fourth-quarter earnings and revenue that exceeded analyst expectations, with adjusted EPS of $2.42 and revenue of $2.24 billion, a 10.9% year-over-year increase. Despite the strong quarterly performance and strategic achievements in 2025, the medical device maker issued a cautious 2026 outlook, with adjusted earnings guidance below consensus, leading to a slight dip in pre-market trading. The company also announced a new $1.5 billion stock repurchase authorization and highlighted its transition to a direct sales organization in the U.S. for long-term growth.

https://au.investing.com/news/earnings/zimmer-biomet-delivers-q4-earnings-beat-cautious-2026-outlook-93CH-4250611

Trending Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Mantle ($MNT) Crypto Forecast: Down 5.1% Today

Binance Coin ($BNB) Crypto Forecast: Down 5.1% Today

XRP ($XRP) Crypto Forecast: Down 5.5% Today

Ethereum ($ETH) Crypto Forecast: Down 5.0% Today

Monero ($XMR) Crypto Forecast: Up 6.1% Today

Prime Medicine ($PRME) Stock Forecast: Down 5.1% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.2% Today

Unity Software ($U) Stock Forecast: Up 5.1% Today

Broadridge Financial Solutions Inc.Common Stock ($BR) Stock Forecast: Down 5.0% Today

Zimmer Biomet Holdings Inc. Price History

13.00.2026 - ZBH Stock was down 2.3%

• During the third quarter of 2025, Nisa Investment Advisors LLC notably decreased its ownership in Zimmer Biomet Holdings, Inc. by 39.8%, potentially indicating a lack of faith in the company's upcoming performance, which might have contributed to the recent market decline.
• Zimmer Biomet Holdings Inc. demonstrated weaker performance compared to its industry counterparts, potentially due to factors beyond what has been publicly revealed, fostering a pessimistic market mood.
• The departure of Mark Bezjak, a vital executive at Zimmer Biomet Holdings, triggered concerns among shareholders regarding leadership stability and future strategic plans, adversely affecting the stock value.
• Following Mark R. Bezjak's appointment at Dentsply Sirona, where he previously held leadership positions at Zimmer Biomet, investors may have grown uneasy about potential competitive shifts towards a rival firm, leading to the downturn in Zimmer Biomet's stock price.

10.01.2026 - ZBH Stock was up 5.3%

• Strong fourth-quarter financial results from Zimmer Biomet exceeded revenue and earnings predictions, leading to the stock's upward trend.
• Despite the positive results, the company's cautious approach to its 2026 guidance, citing the ever-changing healthcare landscape, initially caused a slight decline in pre-market stock prices.
• The strategic shift towards a direct and specialized sales model in the U.S., as highlighted by the CEO, likely bolstered investor confidence in the company's future growth.
• A newly announced $1.5 billion stock repurchase program also contributed to positive investor sentiment and the stock's upward trajectory.

24.01.2025 - ZBH Stock was up 1.7%

• Despite margin concerns and solvency issues, ZBH stock showed a strong bullish movement today.
• The market might have reacted positively to potential cost-cutting measures or strategic initiatives announced by the company to address the challenges.
• Investors could be optimistic about ZBH's ability to navigate through the current macroeconomic uncertainties and pricing pressures, leading to the bullish market movement.

09.03.2025 - ZBH Stock was down 5.1%

• Despite Zimmer Biomet's strategic global expansion efforts and focus on volume growth, the stock faced a bearish movement.
• Rising costs may have outweighed the positive impact of increased demand in the musculoskeletal space.
• Investors might be concerned about the company's ability to effectively manage and control its escalating costs, leading to the downward pressure on the stock price.
• The market sentiment towards the healthcare sector or broader economic factors could also have contributed to the bearish movement in ZBH stock today.

14.00.2026 - ZBH Stock was down 5.2%

• ZBH shares exhibited a significant drop following the company's conservative statements about its future at the J.P. Morgan Healthcare Conference, reflecting concerns among investors about its upcoming performance.
• Despite the recent bearish market movement, evaluations still consider Zimmer Biomet a worthwhile investment opportunity, supported by favorable valuation metrics and financial stability. This indicates that short-term apprehensions may be overshadowing its long-term prospects.
• The decision from Nisa Investment Advisors LLC to sell ZBH shares, alongside other institutional investors increasing their holdings, could have amplified the selling pressure, contributing to the downward trend.
• The recent appointment of Mark R. Bezjak as Group Vice President at Dentsply Sirona, who had a prior role at Zimmer Biomet, might have indirectly influenced the market sentiment towards ZBH, prompting investors to evaluate potential implications on competitiveness and industry dynamics.

07.07.2025 - ZBH Stock was up 9.5%

• The market reacted positively to the upcoming Q2 earnings report for ZBH, with expectations of strength in Hips, Knees, and S.E.T. segments.
• Despite a projected year-over-year earnings dip, investors seem optimistic about the company's performance in key areas.
• This positive outlook could be driving the bullish movement in ZBH's stock price today, as investors anticipate resilience and growth in critical product lines.

07.07.2025 - ZBH Stock was up 7.5%

• ZBH stock saw a strong bullish trend today due to the release of their Q2 earnings and revenue beating expectations, along with an increase in full-year EPS guidance. This positive development suggests promising performance and growth potential for the company.
• Investors reacted positively to ZBH's robust showing in the Hips, Knees, and S.E.T. segments, despite an anticipated decline in year-over-year earnings. The focus appears to be on the overall positive outcomes and updated guidance.
• The market's reaction may also be attributed to ZBH's adept navigation of the competitive medical device industry landscape and its consistent delivery of strong financial results, which has bolstered investor confidence.

04.01.2026 - ZBH Stock was up 2.8%

• ZBH stock experienced a strong bullish movement recently.
• Positive market sentiment was fueled by expectations of increased earnings and higher revenues for the quarter ending December 2025.
• Despite some analyst revisions and a negative Earnings ESP, optimistic growth projections and the company's robust fundamentals likely boosted investor confidence.
• The increase in stake by the National Pension Service and the company's solid reputation as a reliable dividend cornerstone might have positively impacted the stock's performance.

05.10.2025 - ZBH Stock was down 12.5%

• Weak performance in Latin America and specific EU markets affected the projected organic growth, resulting in a decline in the stock value.
• Despite the positive earnings, the stock has been on a downward trajectory in the past year, potentially contributing to the recent bearish trend.
• An uptick in short interest as a percentage of float suggests a growing bearish outlook among investors, adding to the downward pressure on the stock.
• Market sentiment towards Zimmer Biomet Holdings Inc. appears cautious, with investors closely monitoring its performance in key markets.

05.10.2025 - ZBH Stock was down 10.2%

• The decrease in Zimmer Biomet Holdings Inc.'s stock price today could be attributed to the negative trend in its P/E ratio, indicating potential overvaluation concerns among investors.
• The rise in short interest percentage suggests that more investors are betting against the company, possibly due to concerns about its future performance or market conditions.
• These factors combined may have led to a lack of confidence in Zimmer Biomet Holdings Inc.'s stock, resulting in the bearish movement observed today.

05.10.2025 - ZBH Stock was down 15.5%

• Despite Zimmer Biomet exceeding Q3 earnings forecasts, the stock faced a decline in revenue and a reduced outlook, resulting in an early slide.
• Challenges in Latin America and select EU markets affected the company's projected organic growth, contributing to the stock's downward trend.
• The stock price dropped by 0.84% in the latest market session, marking a significant 9.34% decrease over the past year.
• Zimmer Biomet Holdings Inc.'s short interest as a percentage of float has increased, indicating a rise in bearish sentiment among investors.

05.04.2025 - ZBH Stock was down 5.3%

• Zimmer Biomet showed robust earnings in the first quarter, signaling a favorable beginning to the year.
• Despite surpassing earnings expectations, the stock saw a bearish trend following a decrease in the operating margin, sparking concerns among stakeholders regarding profitability.
• The market's response to the decline in operating margin suggests that investors are highly attuned to any indications of financial uncertainties for the company.